- Home
- RAPT vs PROK Comparison
RAPT vs PROK Comparison
Compare RAPT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- PROK
- Stock Information
- Founded
- RAPT 2015
- PROK 2015
- Country
- RAPT United States
- PROK United States
- Employees
- RAPT N/A
- PROK N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RAPT Health Care
- PROK Health Care
- Exchange
- RAPT Nasdaq
- PROK Nasdaq
- Market Cap
- RAPT 117.5M
- PROK 94.9M
- IPO Year
- RAPT 2019
- PROK N/A
- Fundamental
- Price
- RAPT $0.89
- PROK $0.72
- Analyst Decision
- RAPT Buy
- PROK Buy
- Analyst Count
- RAPT 5
- PROK 4
- Target Price
- RAPT $5.25
- PROK $5.00
- AVG Volume (30 Days)
- RAPT 1.1M
- PROK 599.3K
- Earning Date
- RAPT 05-08-2025
- PROK 05-12-2025
- Dividend Yield
- RAPT N/A
- PROK N/A
- EPS Growth
- RAPT N/A
- PROK N/A
- EPS
- RAPT N/A
- PROK N/A
- Revenue
- RAPT N/A
- PROK $306,000.00
- Revenue This Year
- RAPT N/A
- PROK $54.34
- Revenue Next Year
- RAPT N/A
- PROK N/A
- P/E Ratio
- RAPT N/A
- PROK N/A
- Revenue Growth
- RAPT N/A
- PROK N/A
- 52 Week Low
- RAPT $0.71
- PROK $0.46
- 52 Week High
- RAPT $4.60
- PROK $4.28
- Technical
- Relative Strength Index (RSI)
- RAPT 48.13
- PROK 44.42
- Support Level
- RAPT $0.81
- PROK $0.68
- Resistance Level
- RAPT $1.27
- PROK $0.81
- Average True Range (ATR)
- RAPT 0.14
- PROK 0.07
- MACD
- RAPT 0.01
- PROK -0.00
- Stochastic Oscillator
- RAPT 31.55
- PROK 18.57
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.